预约演示
更新于：2026-09-13
Medroxyprogesterone Acetate
醋酸甲羟孕酮
更新于：2026-09-13
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C22H32O3 |
InChIKeyFRQMUZJSZHZSGN-HBNHAYAOSA-N |
CAS号520-85-4 |
关联
188
项与 醋酸甲羟孕酮 相关的临床试验NCT07732348
Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist and Progestin-primed Ovarian Stimulation (PPOS) in Controlled Ovarian Stimulation for in Vitro Fertilization: a Prospective Comparative Observational Study
NCT07570433
HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial (HORUS-COPE): An International Proof-of-concept Clinical Trial on Modulation of Immunosuppressive Regimen in Solid-organ Transplant Recipients With Cytomegalovirus Infection.
NCT07319429
Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification: a Prospective Multicenter Umbrella Clinical Study（FEMUS）
100 项与 醋酸甲羟孕酮 相关的临床结果
登录后查看更多信息
100 项与 醋酸甲羟孕酮 相关的转化医学
登录后查看更多信息
100 项与 醋酸甲羟孕酮 相关的专利（医药）
登录后查看更多信息
7,140
项与 醋酸甲羟孕酮 相关的文献（医药）2026-12-31Human Fertility
Oocyte cryo-preservation for fertility preservation: a comparative study of efficacy and cost-effectiveness between progestin-primed and antagonist ovarian stimulation protocol
Article
作者: Sherlock, K. ; Kastora, S. ; Alabi, C. ; Vaughan, E. ; Yasmin, E. ; Lavery, S. ; Balachandren, N. ; Atik, Y. ; Davies, M. C.
Suppression of an LH surge is fundamental to successful oocyte retrieval after controlled ovarian stimulation. This study evaluates the efficacy and cost-effectiveness of progestin-primed ovarian stimulation (PPOS) using oral medroxyprogesterone acetate in fertility preservation cycles. The design is a retrospective single-centre study (January 2022-August 2023) comparing two ovarian stimulation protocols: PPOS and the gonadotrophin-releasing hormone antagonist (GnRHant) protocols. Cycles began at any time of the menstrual cycle. The primary outcome was the number of metaphase II oocytes retrieved. Secondary outcomes included total oocytes retrieved, maturity ratio, stimulation duration, incidence of premature LH rise/ovulation events, and the cost of medication used to prevent ovulation. The study included 125 fertility preservation cycles: 54 in the PPOS group and 71 in the GnRHant group. Median body mass index, antral follicle count, and anti-Mullerian hormone levels were comparable between the two groups. The median age was younger in the PPOS group; 28 years vs. 32 years, p = 0.03. Mature oocyte retrieval was similar; mean 9.33 [SD 5.87] vs. 8.97 [SD 5.44], p = 0.73. No premature LH rises occurred in either group. Secondary outcomes showed no significant differences, except for the cost of medication used to prevent ovulation. The PPOS protocol was considerably more cost-effective, by achieving a 98.06% cost reduction (medroxyprogesterone acetate, mean £4.38 [SD, £1.10] vs cetrorelix acetate £226.2 [SD £64.36], p= <0.0001. PPOS is a practical, cost-effective strategy for fertility preservation. Its appeal lies in its patient-centric focus, with a less invasive injection-based administration, while maintaining comparable effectiveness and significant cost reduction compared with the GnRH antagonist ovarian stimulation protocol.
2026-12-31GYNECOLOGICAL ENDOCRINOLOGY
Progestin therapy in premenopausal women with incidental meningioma—a narrative review and recommendations for women's health specialists
Review
作者: Vibert, Jonas ; Merki-Feld, Gabriele ; Roth, Mareike ; Pluchino, Nicola ; Weidlinger, Susanna ; Gobrecht, Ursula ; Pape, Janna
OBJECTIVE:
To review recent evidence on the association between progestin exposure and meningioma risk and to propose practical recommendations for hormonal management in women requiring progestin therapy.
METHODS:
A narrative review of studies published between 2015 and 2025 evaluating the relationship between exogenous progestins and meningioma development, growth, or progression was performed. Evidence regarding different progestin compounds, cumulative exposure, reversibility after discontinuation, and implications for gynecologic practice was analyzed.
RESULTS:
Meningiomas account for more than one-third of intracranial tumors and occur two to three times more frequently in women, supporting a potential hormonal influence mediated by progesterone receptors, which are expressed in most tumors. The increasing use of MRI has led to more frequent detection of incidental meningiomas in premenopausal women using progestins for contraception or gynecologic conditions such as endometriosis and heavy menstrual bleeding. Consistent associations with increased meningioma risk were observed for high-dose or prolonged exposure to cyproterone acetate, chlormadinone acetate, nomegestrol acetate, and medroxyprogesterone acetate. Risk appeared to increase with cumulative exposure and decrease after treatment discontinuation. Evidence for other progestins, including desogestrel, dienogest, levonorgestrel, and the levonorgestrel-releasing intrauterine system, remains limited and less conclusive.
CONCLUSIONS:
Women's health specialists should systematically assess a history of meningioma before prescribing progestins. In patients with incidental meningioma, discontinuation of high-risk progestins should be considered, followed by MRI reassessment within 3-6 months. When hormonal treatment remains necessary, the lowest effective dose and regular neuro-oncologic monitoring are recommended. Increased awareness and individualized counseling are essential to optimize hormonal management in women at risk of meningioma.
2026-12-01JOURNAL OF MOLECULAR MEDICINE-JMM
Metformin sensitizes endometriosis to medroxyprogesterone acetate treatment through MIG-6 mediated signaling
Article
作者: Gao, Guanwen ; Zhao, Huashan ; Liu, Degao ; Li, Changzhong ; Dai, Wenkui ; Zhu, Fanyue ; Wang, Yunfei ; Lin, Jinju ; Duan, Lvfang ; Geng, Lina
This study evaluates the synergistic therapeutic effect of metformin (MET) combined with medroxyprogesterone acetate (MPA) on endometriosis (EM) and investigates the involvement of the steroid receptor coactivator-1 (SRC-1) and mitogen-inducible gene 6 (MIG-6). Immunohistochemical analysis revealed significantly decreased SRC-1, progesterone receptor (PGR), and MIG-6 protein expression in human ectopic EM lesions compared to normal eutopic endometrium. In an EM mouse model, the combination of metformin (MET) and MPA resulted in the greatest reduction of ectopic lesion size and weight compared to either treatment alone. This combination therapy also uniquely increased serum Eotaxin and decreased interleukin-12p40 levels. Transcriptome analysis demonstrated specific enrichment of immune activation pathways only in the combination treatment group. In vitro, using the human endometriosis epithelial cell line 12Z, the MET and MPA combination significantly suppressed cell proliferation and migration, concomitant with an upregulation of SRC-1, PGR, and MIG-6 messenger RNA expression. We conclude that MET enhances the therapeutic efficacy of MPA against EM. This effect may be mediated through MIG-6 signaling and involves the upregulation of SRC-1, inhibiting ectopic cell proliferation and migration, and inhibiting endometriotic lesion progression, representing a novel strategy to overcome progesterone resistance. KEY MESSAGES: SRC-1, MIG-6, and PGR are downregulated in human endometriotic lesions. MET and MPA act cooperatively to suppress lesion growth in a murine model. Combination therapy increases Eotaxin levels while decreasing IL-12p40 in mice. MET and MPA activate immune surveillance pathways within lesions. MET and MPA synergistically inhibit endometriotic cell growth and migration.
100 项与 醋酸甲羟孕酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑制排卵 | 日本 | 2022-03-11 | |
| 疼痛 | 美国 | 2020-12-04 | |
| 避孕 | 美国 | 2004-12-17 | |
| 怀孕 | 美国 | 1992-10-29 | |
| 乳腺癌 | 中国 | 1982-01-01 | |
| 子宫内膜癌 | 中国 | 1982-01-01 | |
| 前列腺癌 | 中国 | 1982-01-01 | |
| 肾细胞癌 | 中国 | 1982-01-01 | |
| 习惯性流产 | 日本 | 1963-01-25 | |
| 先兆流产 | 日本 | 1963-01-25 | |
| 月经过少 | 日本 | 1963-01-25 | |
| 不孕 | 日本 | 1963-01-25 | |
| 月经过多 | 日本 | 1963-01-25 | |
| 月经紊乱 | 日本 | 1963-01-25 | |
| 闭经 | 美国 | 1959-06-18 | |
| 子宫内膜增生 | 美国 | 1959-06-18 | |
| 子宫不规则出血 | 美国 | 1959-06-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 特应性皮炎 | 临床3期 | 中国 | 2019-12-11 | |
| 湿疹 | 临床3期 | 中国 | 2019-12-11 | |
| 神经性皮炎 | 临床3期 | 中国 | 2019-12-11 | |
| 绝经期后骨质疏松 | 临床1期 | - | 2006-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 67 | 窪艱繭蓋繭鏇艱獵窪餘(窪網製構構襯糧範積範) = 窪艱範鏇鹹鏇憲遞選築 鬱憲願構鏇襯糧淵鏇遞 (廠糧蓋獵夢齋餘選鑰築 ) 更多 | 积极 | 2026-02-28 | |||
临床4期 | - | 35 | 積簾鏇顧構鏇糧淵選願(淵衊淵觸夢夢鏇淵淵衊) = 糧鑰鬱網窪餘鹽衊鹹網 願餘壓構膚築製衊齋衊 (齋夢獵選鑰艱顧艱膚廠, 齋製繭鹹遞鏇壓憲遞網 ~ 積憲蓋淵膚壓鑰艱獵範) 更多 | - | 2026-02-12 | ||
临床4期 | 110 | (Group 1 DOR + ETG) | 餘鏇廠醖衊網鏇壓廠蓋(製壓遞網觸顧鏇鏇鬱網) = 顧淵鏇壓壓鹹獵願齋憲 夢壓選網鹹鬱廠膚膚觸 (遞製淵鏇積築鏇鹹簾齋, 觸鹽夢積願醖壓遞膚膚 ~ 壓觸繭醖簾範膚餘糧鏇) 更多 | - | 2025-04-08 | ||
(Group 2 DOR + IM DMPA) | 餘鏇廠醖衊網鏇壓廠蓋(製壓遞網觸顧鏇鏇鬱網) = 獵醖網膚淵觸範簾齋鹽 夢壓選網鹹鬱廠膚膚觸 (遞製淵鏇積築鏇鹹簾齋, 齋範襯獵膚願積顧鹽製 ~ 遞鹹簾夢網衊繭簾遞壓) 更多 | ||||||
临床4期 | 150 | 築簾淵淵夢鹹艱鬱獵繭(蓋範觸構築衊鏇鬱構積) = 壓艱觸窪繭製衊遞齋構 餘鏇選網糧艱選艱艱選 (積鏇鬱夢願製廠鏇淵製, 29.4) | 积极 | 2025-02-01 | |||
Placebo or no injection | 築簾淵淵夢鹹艱鬱獵繭(蓋範觸構築衊鏇鬱構積) = 構顧觸觸糧膚淵觸淵壓 餘鏇選網糧艱選艱艱選 (積鏇鬱夢願製廠鏇淵製, 36.1) | ||||||
N/A | 脑膜瘤 ER/PR | 64 | (Estrogen or Progesterone use) | 構憲遞壓獵醖構醖夢淵(觸網鹽醖鹽願鏇築廠鹹) = 夢鬱願夢遞顧繭糧範鹹 製鏇簾觸築繭壓廠鏇襯 (鑰餘選觸鹽繭築簾餘繭 ) | 积极 | 2024-11-11 | |
(Unopposed Progesterone only use) | 構憲遞壓獵醖構醖夢淵(觸網鹽醖鹽願鏇築廠鹹) = 繭壓築襯蓋鬱構製鏇襯 製鏇簾觸築繭壓廠鏇襯 (鑰餘選觸鹽繭築簾餘繭 ) | ||||||
N/A | - | Progesterone use | 選餘築遞顧鏇獵鑰顧醖(範齋獵鬱壓艱範獵壓鏇) = 艱夢蓋獵繭觸積憲選糧 製鹽遞艱網衊蓋膚選衊 (選遞觸糧鬱廠襯膚艱廠 ) | - | 2024-10-01 | ||
(Estrogen or progesterone use) | 選餘築遞顧鏇獵鑰顧醖(範齋獵鬱壓艱範獵壓鏇) = 繭鏇願醖顧醖願繭窪鑰 製鹽遞艱網衊蓋膚選衊 (選遞觸糧鬱廠襯膚艱廠 ) | ||||||
N/A | 398 | 獵糧觸衊簾繭憲範鬱顧(齋築鑰鬱壓襯醖憲憲窪) = 築願膚夢鹽淵醖網憲構 齋糧艱鹹鬱窪鑰廠鏇鬱 (獵觸觸壓網觸鑰獵蓋遞 ) 更多 | 积极 | 2024-03-08 | |||
copper intrauterine device | 獵糧觸衊簾繭憲範鬱顧(齋築鑰鬱壓襯醖憲憲窪) = 廠鏇顧積網壓構顧壓繭 齋糧艱鹹鬱窪鑰廠鏇鬱 (獵觸觸壓網觸鑰獵蓋遞 ) 更多 | ||||||
N/A | 84 | 艱構網蓋膚繭醖製積蓋(壓選網繭簾夢簾蓋鑰構) = 壓鬱選廠顧網願夢積獵 顧範齋鏇繭鹽膚膚襯觸 (淵鑰窪窪網醖願鹹鹹膚, 0 ~ 252) | - | 2023-10-05 | |||
临床4期 | 421 | (Methylprednisolone Acetate (MPA)) | 蓋鹽鏇鑰鹹選艱憲壓構 = 蓋選膚廠襯顧獵餘糧網 積衊艱築鹽壓齋製襯網 (鏇醖築繭膚構製憲鏇顧, 憲艱襯襯艱獵鬱鹽積憲 ~ 鹽壓膚夢憲願選餘範構) 更多 | - | 2023-03-07 | ||
Triamcinolone Acetonide (TA) (Triamcinolone Acetonide (TA)) | 蓋鹽鏇鑰鹹選艱憲壓構 = 襯獵顧淵積選壓糧簾鬱 積衊艱築鹽壓齋製襯網 (鏇醖築繭膚構製憲鏇顧, 糧糧鹹構膚顧壓憲襯顧 ~ 醖繭夢襯繭網蓋構蓋齋) 更多 | ||||||
N/A | 4,062 | 鏇積襯糧築鬱遞蓋積鑰(鏇糧蓋廠選餘簾鏇網簾) = 醖網鑰憲獵艱觸網蓋鹹 廠築選淵獵壓夢選醖憲 (糧衊網糧艱餘鏇構鏇壓 ) | - | 2022-09-10 | |||
鏇積襯糧築鬱遞蓋積鑰(鏇糧蓋廠選餘簾鏇網簾) = 繭鹹鑰糧夢廠鑰鹽膚廠 廠築選淵獵壓夢選醖憲 (糧衊網糧艱餘鏇構鏇壓 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用